Dermapharm Holding SE Capital Expenditures (CapEx) Growth & History (DMP)

Dermapharm Holding SE's capital expenditures (capex) was €42.1M for fiscal 2025.

View full Dermapharm Holding SE company overview

Dermapharm Holding SE annual capital expenditures (capex) history

Dermapharm Holding SE annual capital expenditures (capex)

Fiscal yearPeriod endedCapital expenditures (CapEx)ChangeGrowth
20252025-12-31€42.1M€3.9M+10.15%
20242024-12-31€38.2M−€3.3M−7.95%
20232023-12-31€41.5M€2.5M+6.48%
20222022-12-31€39.0M−€22.2M−36.25%
20212021-12-31€61.2M

Dermapharm Holding SE capital expenditures (capex) trends

Between the periods ended 2021-12-31 and 2025-12-31, Dermapharm Holding SE's capital expenditures (capex) decreased from €61.2M to €42.1M, a change of −€19.1M. The latest reported quarter, Q2 2026, shows €14.9M.

About the metric

What capital expenditures (CapEx) mean

Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.

Calculation and source

reported capital expenditures

TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company official filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Dermapharm Holding SE source filings ↗

Community posts

It’s quiet here.

No posts about DMP yet. Start the conversation.

Write the first post